The Same Promise, The Same Betrayal
Wherever cannabis has been legalised, the pitch has sounded familiar: jobs, rural upliftment, new revenue, and patient access. Politicians spoke of transformation. Investors were told to expect a sunrise industry. Farmers were promised a future beyond criminalisation.
But years later, the results look eerily alike. Farmers excluded. Patients priced out. Communities sidelined. Corporates consolidating power. The details differ, but the pattern is unmistakable.
A global system designed to monopolise cannabis under the guise of regulation.
This is not failure. It is the playbook.
Licensing as a Gate, Not a Gateway
The first tool is licensing. Everywhere it appears, it is presented as consumer protection. In reality, it works as a gatekeeping mechanism.
Canada demanded millions in upfront investment just to apply. Germany awarded domestic cultivation rights to only three companies, all tied into pharmaceutical networks. Australia forced operators into expensive build-first models, while New Zealand required fees upfront before even looking at an application. South Africa followed suit, demanding compliant facilities before a licence could even be considered.
In the United States, some states wrote monopoly directly into the rules. Florida required vertical integration—grow, process, and retail under one licence—combined with a hard cap on the number of licences. The effect was obvious: only the richest operators could play, and once inside, they controlled the entire supply chain.
Agriculture usually runs on provisional licences and staged approvals. In cannabis, the sequence is reversed. Regulators hold no risk. Farmers and investors carry all of it.
The barrier is not accidental. It is design.
Pharma Framing: From Plant to Pill
The second move is framing. Cannabis, a plant grown for centuries, is reclassified as medicine.
And medicine means pharmaceutical control.
Germany requires patients to go through pharmacies, with insurers deciding what is reimbursed. In the UK, CBD was trapped in the “novel foods” regime, wiping out hundreds of small brands and leaving the field to corporates. Spain’s draft decree channels cannabis through specialist prescriptions and hospital dispensing, locking agriculture out of the picture before it even began.
Portugal is similar. Since 2018, medical cannabis has been available, but only via pharmacies under INFARMED control. Prescriptions remain low, while corporate exports thrive. Early pricing was set at €150 for just 15 grams—proof that the regulatory framing was designed around corporates, not patients.
The language is always safety. The outcome is always monopoly.
By forcing cannabis into the pharmaceutical box, governments sideline agriculture and hand control to labs, distributors, and corporates.
Oversupply and Delay: The Double Bind
Where regulators throw the gates too wide, oversupply becomes the weapon. In Canada, licences flooded the market. Prices collapsed. Small operators folded. Consolidation followed, with giants like Tilray and Canopy swallowing the survivors.
Where regulators drag their feet, delay achieves the same end. In the UK, patients still face some of the worst access in Europe despite years of promises. In New Zealand, compliance hurdles stalled progress for years. In South Africa, workshops and white papers pile up while traditional farmers remain criminalised.
Thailand demonstrates another lever: whiplash. In 2022 it decriminalised cannabis, sparking a boom in dispensaries. By 2025, the government reversed course, restricting cannabis back into a tightly controlled “medical-only” box. Small domestic actors were wiped out. Larger players with capital and connections could adapt.
Whether through oversupply, delay, or sudden reversals, independents are weakened, and corporates tighten their hold.
Donor Optics: Promises as Currency
In the global South, cannabis is leveraged as aid theatre. Governments promise rural upliftment to development agencies and foreign investors. Lesotho, Zimbabwe, Malawi—each was rolled out as a showcase for donor goodwill.
But licences went almost exclusively to foreign-backed corporates and elites. In Malawi, licence fees are openly pegged to fund the regulator, putting them far beyond the reach of local farmers. In Zimbabwe, renewal costs alone could cripple a small grower. And in Lesotho, the first licences went to foreign firms while local communities remained criminalised.
Here, cannabis reform was never about development. It was about optics. A bargaining chip to unlock donor funding while keeping real change at bay.
Regulators on Cost-Recovery
Beneath it all sits a quieter mechanism. How regulators fund themselves.
In Canada, the Cannabis Fees Order explicitly funds the regulator via annual licence charges and revenue-linked fees. In Australia, the Office of Drug Control is run on a cost-recovery model. New Zealand’s Medicinal Cannabis Agency requires full fees upfront before it will even begin assessing an application. In the UK, the Food Standards Agency uses a paid Novel Foods process for CBD, squeezing out hundreds of smaller brands.
The incentive is obvious. More applications, renewals, and inspections mean more income. Complexity keeps the revenue stream flowing.
When regulators depend on fees to survive, the system naturally skews toward restriction and control.
To What End?
The machinery looks different in each country, but the motives converge.
- Protect monopolies by ensuring only corporates can comply.
- Preserve regulator revenue streams through cost-recovery.
- Leverage cannabis promises for donor optics and international credibility.
- Maintain control by preferring corporates and labs to farmers and communities.
This is not about protecting health. It is about preserving power.
Winners and Losers
Winners:
- Corporates with capital and connections.
- Regulators insulated by fee streams.
- Governments who court donors and investors with optics.
Losers:
- Farmers excluded by impossible compliance.
- Patients paying inflated prices or left without access.
- Communities whose plant has been turned into another system of extraction.
The Harsh Truth
The cannabis monopoly is not incompetence. It is not an accident. It is a system that repeats across borders with uncanny precision.
Raise barriers. Narrow the frame. Stall the market. Extract fees. Call it protection. Call it transformation.
The result is always the same.
Exclusion.
Closing Call
Cannabis legalisation was sold as freedom, fairness, and opportunity. Instead, it has been folded into the same global machinery that governs every other resource: monopolies protected, communities excluded, promises broken.
Until governments move from theatre to genuine reform — domestic markets, tiered compliance, community inclusion — the green rush will remain a mirage.
The plant may be free. But the people are not.
Unless the playbook is broken, they never will be.
Freelance Writer & Storyteller | Co-Creator | Science, Agriculture & Tech | Health, Fitness & Resilience | Founder, Forge_50+
#
